SAN FRANCISCO, May 3 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that David Hung, M.D., president and chief executive officer, will participate in two upcoming healthcare conferences. He will present at the UBS Global Generic & Specialty Pharmaceuticals Conference on Wednesday, May 9, at 8:30 a.m. Eastern time at the Grand Hyatt in New York. The following week, he will present at the Rodman & Renshaw 4th Annual Global Healthcare Conference on Monday, May 14, at 9:45 a.m. local time at Le Meridien Beach Plaza Hotel at the Sea Club in Monte Carlo, Monaco.
Dr. Hung will provide an overview of Medivation and its clinical development program for Dimebon(TM) for Alzheimer's and Huntington's diseases.
A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay will also be available for 30 days following each live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
Medivation, Inc.CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; Jani Bergan, WeissComm Partners, +1-415-946-1064
Web site: http://www.medivation.com//
